| abstract |
The use of PAF (platelet activating factor) antagonists (I) and anticholinergics (II) for treatment of bronchial asthma is new. Also claimed are the use of (I) of hetrazepinoid structure in combination with (II) for therapeutic treatment of bronchial asthma; and pharmaceutical compsns. contg. (I) and (II). (I) are thieno (3,2-b)(1,2,4)triazolo (4,3-a)(1,4)diazepine derivs. (or tetracylic and/or thieno- imidazo- diazepine analogues). USE/ADVANTAGE - Simultaneous use of (I) and (II) for treatment of bronchial asthma gives a dose-dependent, synergistic increase in the anti anaphylactic/antiallergic activity of (I). (I) and (II) may be administered simultaneously by inhalation in the same formulation, e.g. an aerosol. Alternatively, (II) is administered by inhalation and (I) is administered orally or parenterally. The dose of (I) depends on the relative PAF receptor binding affinity; typically the oral dose of WEB 2086 as (I) is 40-2000 (esp. 90-120) mg. The combination of (I) and (II) may also be used for treating other chronic obstructive respiratory tract disorders, e.g. bronchitis. |